MICTONORM® PROPIVERINE FOR URINARY INCONTINENCE Another anticholinergic, no more.





PEUTIC MODEST THERAPEUTIC INNOVATION



VALUE IN SPECIFIC SITUATIONS



INSUFFICIENT EVIDENCE

×х



WHAT IS IT?

Urinary antispasmodic with antimuscarinic properties.

INDICATION

Symptomatic treatment of urinary incontinence and / or increased urinary frequency and urgency in patients with overactive bladder syndrome.

POSOLOGY AND METHOD OF ADMINISTRATION

One capsule (30 mg) once a day, with or without food. It is recommended to reevaluate the effectiveness after 4 weeks of treatment.

EFFECTIVENESS

Compared to tolterodine 4 mg: There are no differences in effectiveness in reducing the number of episodes of urination in 24 hours. No inferiority.

RISKS

Anticholinergic effects: dry mouth, headache, accommodation disturbances, visual impairment, constipation, abdominal pain, dyspepsia and fatigue.

Liver function: reversible alterations of liver enzymes may occur, so they should be monitored in long-term treatments. It is not recommended in patients with moderate to severe hepatic impairment.


Caution: in patients with autonomic neuropathy, severe congestive heart failure, prostatic hypertrophy, hiatus hernia with esophageal reflux, arrhythmias and angle-closure glaucoma. In the elderly, risk of cognitive impairment.

PLACE IN THERAPEUTICS

Efficacy and safety similar to tolterodine. Like other drugs of the same class, it would only be indicated when the non-pharmacological measures are insufficient.

PRESENTATIONS

Mictonorm[®] 30 mg, 28 capsules of modified release (30.91 €).







The qualification has been assigned jointly by the New Medicines Evaluation Committees of Andalusia, Castilla y León, País Vasco, and Navarra. This information is subject to modifications depending on the evolution of scientific knowledge. Notify the suspicions of adverse reactions in www.notificaram.es